You are here: Home: Meet The Professors - Renal 1 | 2008: Faculty Affiliations and Disclosures

Content Validation and Disclosures

Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr Vogelzang — Advisory Committee: Amgen Inc, Genentech BioOncology, GPC Biotech; Clinical Trials: Bayer Pharmaceuticals Corporation, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc; Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis; Paid Research: Onyx Pharmaceuticals Inc; Speakers Bureau: Bayer Pharmaceuticals Corporation, Pfizer Inc, Sanofi-Aventis, Schering-Plough Corporation, Wyeth. Dr Motzer — Advisory Committee:Novartis Pharmaceuticals Corporation; Paid Research: Novartis Pharmaceuticals Corporation, Pfizer Inc, Wyeth; Speakers Bureau: Bayer Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc.

COMMUNITY PANEL — Drs Dresdner, Moriarty and Taub had no real or apparent conflicts of interest to disclose. Dr Joshua — Stock Ownership: Amgen Inc, Genentech BioOncology. Dr Leighton — Paid Research: Amgen Inc, Bristol-Myers Squibb Company, Novartis Pharmaceuticals Corporation; Speakers Bureau: Sanofi- Aventis.

MODERATOR — Dr Love does not receive any direct remuneration from industry. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Eli Lilly and Company, Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline, ImClone Systems Incorporated, Merck and Company Inc, Millennium Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Ortho Biotech Products LP, OSI Oncology, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis, Synta Pharmac

RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

Medical Oncologist Community Panel

David M Dresdner, MD Saint Anthony’s Hospital St Petersburg, Florida Gracy Joshua, MD Board Certified in Oncology Private Practice Lake Worth, Florida Chief of Oncology JFK Medical Center Atlantis, Florida

John C Leighton Jr, MD Associate Director, Albert Einstein Cancer Center Philadelphia, Pennsylvania Daniel J Moriarty, MD Medical Director, Oncology Center at Overlook Hospital Summit, New Jersey

Matthew A Taub, MD, PA Pembroke Pines, Florida